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Abstract
In mammals, estrogens have a multiplicity of effects ranging from control of differentiation of selected brain nuclei,
reproductive functions, sexual behavior. In addition, these hormones influence the manifestation of disorders like depression and
Alzheimer’s. Study of the cells target for the hormone has shown that estrogen receptors (ERs) are expressed in all known neural
cells, including microglia. In view of the potential interest in the use of estrogens in the therapy of several pathologies of the
nervous system, it would be of interest to fully understand the mechanism of estrogen activity in the various neural target cells
and get an insight on the molecular means allowing the hormone to display such a variety of effects. We have proposed the use
of a reductionist approach for the systematic understanding of the estrogen activities in each specific type of target cell. Thus, we
have generated a model system in which to study the activation of one of the known (ERs), estrogen receptor alpha. This system
allowed us to identify a number of novel genes which expression may be influenced following the activation of this receptor
subtype by estradiol (E2). We here report on data recently obtained by the study of one of these target genes, nip2, which encodes
a proapoptotic protein product. We hypothesize that nip2 might be an important molecular determinant for estrogen anti-apop-
totic activity in cells of neural origin and represents a potential target for drugs aimed at mimicking the E2 beneficial effects in
neural cells. © 2000 Elsevier Science Ltd. All rights reserved.
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1. Introduction
In the last decade, evidence has been accumulated that
the role of estradiol (E2) in the mammalian central
nervous system (CNS) goes far beyond the control of
reproductive functions. E2 acts both in developing and
in mature brain; during the differentiation of the nervous
system it seems to regulate the differentiation of selected
subsets of neurons [4]; in the mature brain E2 has a
beneficial influence on memory mechanisms [28,39] and
on affective behavior [51] and it delays the onset of
neurodegenerative disorders like Alzheimer’s disease
[19,45,10,13,26]. The understanding of the molecular
mechanisms supporting E2 positive effects would be of
interest for the development of novel, specific drugs.
However, the multiplicity of estrogen functions in neural
cells reflects a complexity of action which limits the
elucidation of its activities in molecular terms.
1.1. E2 may modulate neural cell acti6ities through a
6ariety of mechanisms
The factors contributing to heterogeneous responses
to E2 in the nervous system are due to, (a) the multiplic-
ity of estrogen receptors (ERs); (b) the nature of estrogen
target cells; (c) the heterogeneity of signals which can
activate intracellular ERs.
1.1.1. Multiplicity of ERs
It is well known that estrogens bind intracellular
receptors members of a superfamily of hormonally-regu-
lated transcription factors [47]. So far, two estrogen
binding proteins have been described and named estro-
gen receptor a and b (ERa and ERb) [27,25,46,15]. Both
receptors reside in the target cell nucleus in a complex
together with inhibitory proteins (heat shock proteins,
such as Hsp90 and others).
The cognate hormone by binding the receptor deter-
mines the release of the inhibitory proteins; the estrogen-
ER complex can at this point recognize specific
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DNA sequences (named estrogen responsive elements)
in the promoter of target genes, whereby recruits the
proteins of the transcription apparatus and triggers the
synthesis of specific mRNAs. Alternatively, the ligand-
activated receptors without binding to the DNA may
directly interact with elements of the transcription ma-
chinery and modulate the activity of other transcription
factors (e.g. NFkB, AP-I, SFRE [43,49]. The genes
coding for ERa and b share a high degree of structural
homology [27], particularly in the DNA binding (96%)
and in the hormone binding (53%) domains. The N-ter-
minus is the least homologous (30%); it is conceivable
that this domain might establish distinct interactions
with the proteins of the transcription apparatus and be
responsible for a differential activity of the two recep-
tors. So far, however, very little experimental evidence
supports a different role of the two receptors once
expressed in the same cell system. To verify whether the
two receptors have a differential function, we studied a
very well known effect of E2 in neural cells, neurite
sprouting. By transient transfection of SK-N-BE cells
with one of the two receptors at a time we demon-
strated that, in the same cell, E2 (1 nM) induced a
significantly different morphology in cells expressing
ERa or b (Fig. 1). This observation suggests that the
two receptors have a distinct effect on the same target
cell. We actually proved that this is indeed the case by
cotransfecting with ERa or b dominant negative mu-
tants of the small G protein Rac1b, known to play an
important role in microtubule assembly. This experi-
ment demonstrated that the signaling pathway of ERa,
but not ERb, involves this small G protein further
substantiating our hypothesis (Fig. 2) [36]. In addition
to the above mentioned intracellular receptors, several
authors have recently proposed the existence of mem-
brane receptors for estrogens [32] Smith et al., 1989,
[50,33,18,38], the evidence for this hypothesis being
electrophysiological studies which indicate a functional
link between membrane E2-binding proteins and cal-
cium channels. There are also a number of studies
showing E2-dependent activation of other transduction
signaling molecules (cAMP, [17], Ca2 [22,21], inositol-
3-phosphate kinase, diacylglicerol, src [5], CREB,
ERK-1, ERK-2 [44] further suggesting the possibility
that E2 binds to acceptor sites located in the cytoplas-
mic membrane.
These putative membrane receptors, however, are
still unknown from the biochemical point of view.
Fig. 1. Transient transfection of ERa or b cDNA results in a differential morphogenetic response to estradiol of neuroblastoma SK-N-BE cells.
The experiment was carried out by transient transfection of SK-N-BE cells with ER or ERb cDNA together with bGAL DNA to identify the cells
positively transfected [36]. As we showed also with stable transfections, the estrogen-dependent activation of SK-N-BE cells expressing ERa results
in a morphological change which can be quantitated by assessing the extent of neurite elongation and the number of neurites generated at a fixed
day (e.g. sixth day following the treatment with the hormone). The morphological change induced by estradiol was significantly different in cells
transfected with ERb. In this case, SK-N-BE morphological differentiation lead to the generation of uni- or bi-polar cells with morphology clearly
distinguishable from cells transfected with the ER subtype. Upper panels: SK-N-BE cells transiently transfected with plasmids coding for bGAL
alone (left), ER and bGAL (middle), ERb and bGAL (right). Lower panels: The cells transfected as above were treated for 6 days with 1 nM E2.
ERa-expressing cells (middle) acquire a star-shaped morphology with an average of four to five neurites per cell, while ERb-transfected cells (right)
show a bipolar structure with a maximum of two neurites per cell.
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Fig. 2. In SK-N-BE cells different signal transduction molecules are responsible for the estrogen-dependent morphological changes. Transfection
studies carried out with dominant negative mutants of small G proteins show that the morphological changes induced by E2 require active Rac1b
only in cells transfected with ERa. The presence of dominante negative mutants of Rac1b or Rac1a does not interfere with the morphological
changes induced by activated ERb [36].
1.1.2. All neural cell types may be target for estrogen
acti6ity
Intracellular ERs can be found in all the neural cells,
neurons and glial cells like oligodendrocytes and astro-
cytes [23,40]. In addition, recent, unpublished results
from our laboratory, show that ERs are present also in
rat microglial cells (Vegeto et al., unpublished data).
Interestingly, localization studies indicate that ERa and
b are generally expressed in different areas of the CNS
[41,42,3]. It is conceivable, therefore, that in each spe-
cific target cell the estrogen triggers differential re-
sponses by activating selected target genes.
1.1.3. Acti6ation of ER in the absence of the cognate
ligand
Studies originally carried out in O’Malley’s labora-
tory [37] and then by several other authors
[20,6,30,24,34,35] have shown that ERa can be tran-
scriptionally activated by neurotransmitters and growth
factors also in the absence of the cognate ligand. In
particular, dopamine [37], insulin, IGF-1 [30] and EGF
[20] may control ERa transcriptional activity, possibly
by phosphorylation of the receptor itself or of the
coactivators:repressors interacting with it [6,24,35]. This
interaction between intracellular and membrane recep-
tors has been referred to as cross-talk (Fig. 3).
In view of the number of cells and genes targeted by
this multifunctional receptor, the finding of differential
mechanisms controlling its transcriptional activation
leads to hypothesize that the above-mentioned cross-
talk has evolved in order to limit the large ER potential
by appropriate, differential hormone stimuli. We have
proposed that this mechanism may be of relevance
especially during the differentiation of the CNS [34] by
allowing IGF-I to activate the ER. This would explain
why, at least in rat, ERs are synthesized in several brain
areas very early during the differentiation of the CNS
while the high levels of circulating alpha-fetoproteins
restrain estrogen access to the target cells [48].
1.2. SK-ER3 neuroblastoma cells, a tool for the
understanding of the molecular e6ents induced by
estrogens in neural cells
The obvious consequence to what is said above is
that the understanding of the molecular events trig-
gered by the hormone-receptor complex in the whole
brain tissue is not informative because any effect on
target gene activities could represent the summation of
a series of responses to the hormone in the various
target cells. On this line of thought, a few years ago we
proposed to generate a neuroblastoma cell line in which
the activities of a single receptor (ERa) [29] could be
systematically studied in a specific cell system. To this
goal, we stably transfected hERa cDNA in the human
neuroblastoma cell line (SK-N-BE). We then character-
ized the cell line generated (Fig. 4) and (i) proved that
it contains a number of receptors similar to other
estrogen target cells (about 200 fmoles:mg cytosolic
protein), (ii) that the hormone and DNA binding activ-
ity of the transfected receptors are indistinguishable
from those previously reported in other cell lines and
(iii) that the receptor is transcriptionally active [29].
Interestingly, our studies showed that in the SK-ER3
cell line the E2-dependent activation of ERa results in
growth arrest and differentiation towards the dopamin-
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ergic phenotype [1,2]. In view of the close links between
the dopaminergic system and estrogen responsive cells
in the CNS we proposed that the cell line we generated
might recapitulate at least some of the events occurring
during the differentiation of the CNS and continued
our studies with the identification of genes regulated by
estrogens in cells of neural origin. The technique ap-
plied was differential display PCR. We were able to
isolate 11 DNA fragments representing genes modu-
lated by E2, in SK-ER3 model system [14].
The question thus arising, regarded the physiological
relevance of the genes identified in E2 action in neural
cells.
1.2.1. Nip2, a protein product whose expression
correlates with cell death
One of the genes whose expression was negatively
modulated by E2, nip2, had been described earlier by
Boyd [11] as coding for a Bcl-2 binding protein. We,
therefore, initiated a series of experiments aimed at
clarifying the role of nip2 in cell activities.
1.2.1.1. O6erexpression of nip2 correlates with cell death.
We initially observed the consequences of nip2 overex-
pression in neuroblastoma cells. A series of transient
transfections proved that nip2 overexpression resulted
in rapid cell death. The effect was dose-dependent [31]
and could be blocked by Bcl-2 coexpression [9]. Further
proof of the correlation between cell death and overex-
pression of nip2 was obtained by measuring the content
of nip2 mRNA in cells exposed to toxic stimuli. All the
neurotoxic agents, glucose deprivation, calcium
ionophore, b-amyloid peptide, determined a rapid in-
crease in nip2 expression which was then followed by
the onset of pre-apoptotic events, like change in mem-
brane polarity, and by cell death.
1.2.1.2. E2 down regulates nip2 expression and blocks
neuroblastoma cell apoptosis. In SK-ER3 cells, treat-
ment with 10 nM E2 results in a significant decrease of
nip2 mRNA levels. Time course studies show that this
effect is maximal at 4 h and then decreases with time.
At 24 h after the treatments, nip2 mRNA levels are
back to control values [31]. Interestingly, in the same
study, in a time course experiment taking into consider-
ation the efficacy of E2 anti-apoptotic activity we
showed that E2 may counteract the effect of neurotoxic
agents only if it is administered before the toxic com-
pounds and the protective effect of E2 is maximal when
given 16 h before the toxic insult. These observations
led us to hypothesize that the down-modulation of nip2
expression might be instrumental in the anti-apoptotic
activity of E2 in neuroblastoma cells.
Fig. 3. Differential pathways involved in intracellular ER activation. Estrogen responsive genes can be modulated by activation of both
intracellular and membrane receptors. The former can, in their turn, be activated through a ligand-dependent (A) or ligand-independent (B)
pathway, which involves phosphorylation by different kinases, among which mitogen-activated protein kinases (MAPK). Membrane receptors (C)
have not been biochemically characterized yet, but their existence is suggested by several lines of experimental evidence. Reports carried out by
several authors in different estrogen target tissues suggest that estrogens may elicit very rapid (observed in ms) intracellular changes, which cannot
be the result of a genomic action of the E2-ER complex.
A. Maggi et al. : Journal of Steroid Biochemistry & Molecular Biology 74 (2000) 319–325 323
Fig. 4. The SK-ER3 neuroblastoma cell line as a model system for the study of estrogen effects in neural cells. The ERa expressed in SK-ER3
cells has ERa hormone-binding, DNA-binding and transcriptional activities identical to other cells expressing the receptor. Prolonged treatment
with 1 nM E2 (16 h) induces a series of intracellular events resulting in a differentiation towards a dopaminergic phenotype. Photographs on the
right show the morphological differentiation of SK-ER3 cells 12 days after treatment with E2; the intense staining with anti-tyrosine hydroxylase
antibodies show that SK-ER3 cells have acquired a dopaminergic phenotype [1,2].
2. Discussion
In the latest years, several authors have shown that
E2 exerts anti-apoptotic activity in neural cells exposed
to a variety of toxic insults [7,19,8,16]. The mechanisms
involved in this activity is still controversial since sev-
eral authors favor a non genomic-, while others a
genomic-mediated effect of the hormone. Our studies
indicate that E2 may modulate the synthesis of factors
relevant in the apoptotic cascade of events and there-
fore point to the importance of E2-dependent genomic
effects in neural cell protection against toxic stimuli.
While the effects of E2 on nip2 activity await to be
further studied in in vivo models, it is important to
underlay that the neuroprotective effects of estrogens
may be the result of a series of activities exerted on the
different cell types present in the CNS. For instance,
estrogens may enhance the synthesis and secretion of
growth factors from glial cells as well as exert anti-
inflammatory activities in microglia [12]. These activi-
ties would contribute to enhance the survival of
neurons and to limit the accumulation of toxic sub-
stances, respectively. We are therefore focusing on the
effect of the hormone also in cells other than neurons.
Our studies provide some background for the under-
standing of the molecular signaling underlying E2 pro-
tective effects, which might be of interest also for cells
other than neural (e.g. mammary gland). The finding of
specific target for estrogen action may lead to the
design of novel drugs aimed at reproducing the benefi-
cial effects of the hormone, in the absence of the
undesired ones.
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